7318. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial.
作者: Robert Croop.;Richard B Lipton.;David Kudrow.;David A Stock.;Lisa Kamen.;Charles M Conway.;Elyse G Stock.;Vladimir Coric.;Peter J Goadsby.
来源: Lancet. 2021年397卷10268期51-60页
Rimegepant is a calcitonin gene-related peptide receptor antagonist that has shown efficacy and safety in the acute treatment of migraine. We aimed to compare the efficacy of rimegepant with placebo for preventive treatment of migraine.
|